Wells Fargo’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17M Sell
84,901
-47,735
-36% -$9.44M ﹤0.01% 1634
2025
Q4
$25.1M Buy
132,636
+17,459
+15% +$3.35M ﹤0.01% 1343
2025
Q3
$20.4M Buy
115,177
+101,936
+770% +$15.2M ﹤0.01% 1459
2025
Q2
$1.51M Buy
13,241
+436
+3% +$46.6K ﹤0.01% 3428
2025
Q1
$1.35M Buy
12,805
+1,585
+14% +$179K ﹤0.01% 3463
2024
Q4
$1.2M Buy
11,220
+2,570
+30% +$291K ﹤0.01% 3574
2024
Q3
$866K Sell
8,650
-161
-2% -$16.2K ﹤0.01% 3641
2024
Q2
$742K Buy
8,811
+1,961
+29% +$156K ﹤0.01% 3677
2024
Q1
$501K Buy
6,850
+1,170
+21% +$86.3K ﹤0.01% 3891
2023
Q4
$406K Buy
5,680
+1,169
+26% +$69K ﹤0.01% 4004
2023
Q3
$270K Sell
4,511
-3,352
-43% -$221K ﹤0.01% 4167
2023
Q2
$567K Buy
7,863
+3,721
+90% +$279K ﹤0.01% 3850
2023
Q1
$305K Buy
4,142
+2,140
+107% +$152K ﹤0.01% 4171
2022
Q4
$134K Sell
2,002
-2,270
-53% -$148K ﹤0.01% 4396
2022
Q3
$230K Sell
4,272
-378
-8% -$22.2K ﹤0.01% 4165
2022
Q2
$259K Sell
4,650
-30,143
-87% -$1.71M ﹤0.01% 4145
2022
Q1
$2.44M Sell
34,793
-24,791
-42% -$1.8M ﹤0.01% 3102
2021
Q4
$5.74M Sell
59,584
-10,983
-16% -$1.01M ﹤0.01% 2430
2021
Q3
$6.13M Buy
70,567
+12,471
+21% +$965K ﹤0.01% 2647
2021
Q2
$4.75M Sell
58,096
-8,401
-13% -$699K ﹤0.01% 2919
2021
Q1
$6.32M Buy
66,497
+10,025
+18% +$948K ﹤0.01% 2609
2020
Q4
$3.5M Sell
56,472
-30,807
-35% -$1.76M ﹤0.01% 3050
2020
Q3
$5.19M Sell
87,279
-32,303
-27% -$2.2M ﹤0.01% 2462
2020
Q2
$8.34M Sell
119,582
-30,735
-20% -$1.95M ﹤0.01% 2007
2020
Q1
$6.82M Buy
150,317
+68,141
+83% +$3.86M ﹤0.01% 1998
2019
Q4
$5.35M Sell
82,176
-24,443
-23% -$1.63M ﹤0.01% 2508
2019
Q3
$6.62M Buy
106,619
+4,107
+4% +$258K ﹤0.01% 2297
2019
Q2
$7.3M Buy
102,512
+1,898
+2% +$140K ﹤0.01% 2220
2019
Q1
$7.89M Sell
100,614
-554,585
-85% -$42M ﹤0.01% 2123
2018
Q4
$55.5M Buy
655,199
+225,254
+52% +$24M 0.02% 768
2018
Q3
$73.6M Sell
429,945
-40,927
-9% -$6.17M 0.02% 723
2018
Q2
$60.9M Buy
470,872
+13,339
+3% +$1.49M 0.02% 814
2018
Q1
$47.1M Sell
457,533
-82,574
-15% -$8.17M 0.01% 933
2017
Q4
$46.1M Sell
540,107
-1,843
-0.3% -$160K 0.01% 932
2017
Q3
$46M Buy
541,950
+36,101
+7% +$2.86M 0.01% 914
2017
Q2
$38.3M Buy
505,849
+16,706
+3% +$1.17M 0.01% 1002
2017
Q1
$32.3M Sell
489,143
-809,327
-62% -$53.2M 0.01% 1101
2016
Q4
$82.3M Sell
1,298,470
-176,268
-12% -$11.1M 0.03% 586
2016
Q3
$93.9M Buy
1,474,738
+224,342
+18% +$16.5M 0.03% 532
2016
Q2
$93M Sell
1,250,396
-94,850
-7% -$7.04M 0.04% 494
2016
Q1
$89.9M Buy
1,345,246
+464,516
+53% +$28.2M 0.04% 504
2015
Q4
$59.6M Buy
880,730
+506,991
+136% +$31.3M 0.02% 680
2015
Q3
$20M Buy
373,739
+123,788
+50% +$7.51M 0.01% 1304
2015
Q2
$15.7M Sell
249,951
-23,014
-8% -$1.26M 0.01% 1543
2015
Q1
$13.1M Buy
272,965
+42,994
+19% +$1.65M 0.01% 1640
2014
Q4
$7.63M Sell
229,971
-64,789
-22% -$2.11M ﹤0.01% 2016
2014
Q3
$8.64M Sell
294,760
-232,128
-44% -$7.71M ﹤0.01% 1903
2014
Q2
$20.5M Buy
526,888
+65,229
+14% +$2.65M 0.01% 1270
2014
Q1
$19.4M Buy
461,659
+164,144
+55% +$6.84M 0.01% 1287
2013
Q4
$9.76M Sell
297,515
-35,441
-11% -$1.15M ﹤0.01% 1740
2013
Q3
$8.99M Buy
332,956
+55,740
+20% +$1.57M ﹤0.01% 1726
2013
Q2
$6.47M Buy
+277,216
New +$4.99M ﹤0.01% 1907

Other funds holding LGND

Wells Fargo's LGND Position: Q1 2026 in Review

Wells Fargo reduced its Ligand Pharmaceuticals (LGND) stake by 36% in Q1 2026, selling an estimated $9.44M and leaving 84,901 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

Wells Fargo first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $93.9M in Q3 2016. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Wells Fargo held 84,901 shares of Ligand Pharmaceuticals worth $17M as of Q1 2026.
  • Wells Fargo sold 47,735 Ligand Pharmaceuticals shares in Q1 2026, an estimated $9.44M.
  • Ligand Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1634 holding.
  • Wells Fargo first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Ligand Pharmaceuticals position peaked at $93.9M in Q3 2016.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.